anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The endotracheal tube (ETT) affords support for intubated patients, but the increasing incidence of ventilator-associated pneumonia (VAP) is jeopardizing its application. ETT surfaces promote (poly)microbial colonization and biofilm formation, with a heavy burden for VAP. Devising safe, broad-spectrum antimicrobial materials to tackle the ETT bioburden is needful. Herein, we immobilized ciprofloxacin (CIP) and/or chlorhexidine (CHX), through polydopamine (pDA)-based functionalization, onto poly(vinyl chloride) (PVC) surfaces. These surfaces were characterized regarding physicochemical properties and challenged with single and polymicrobial cultures of VAP-relevant bacteria (Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis) and fungi (Candida albicans). The coatings imparted PVC surfaces with a homogeneous morphology, varied wettability, and low roughness. The antimicrobial immobilization via pDA chemistry was still evidenced by infrared spectroscopy. Coated surfaces exhibited sustained CIP/CHX release, retaining prolonged (10 days) activity. CIP/CHX-coated surfaces evidencing no A549 lung cell toxicity displayed better antibiofilm outcomes than CIP or CHX coatings, preventing bacterial attachment by 4.1-7.2 Log10 CFU/mL and modestly distressingC. albicans. Their antibiofilm effectiveness was endured toward polymicrobial consortia, substantially inhibiting the adhesion of the bacterial populations (up to 8 Log10 CFU/mL) within the consortia in dual- and even inP. aeruginosa/S. aureus/C. albicans triple-species biofilms while affecting fungal adhesion by 2.7 Log10 CFU/mL (dual consortia) and 1 Log10 CFU/mL (triple consortia). The potential of the dual-drug coating strategy in preventing triple-species adhesion and impairing bacterial viability was still strengthened by live/dead microscopy. The pDA-assisted CIP/CHX co-immobilization holds a safe and robust broad-spectrum antimicrobial coating strategy for PVC-ETTs, with the promise laying in reducing VAP incidence.
To the best of our knowledge, no study has investigated the balance between the endogenous anti-nociceptive properties of the individual and the anaerobic-evoke pro-nociceptive activity in determining the maximal performance during anaerobic exercise. Moreover, the interaction between psychological factors and pro- and anti- nociceptive processes that are operated during anaerobic exercise, need to be investigated.

Methods: Forty healthy men and women, between the ages of 18-40 will be involved in the study. Each participant will complete 3 psychological questionnaires regarding their personality traits: Pain Catastrophizing Scale (PCS), State-Trait Anxiety Inventory and Perceived Stress Questionnaire. Pain psychophysics tests will be used for evaluating the individual pain perception, prior and subsequent to the anaerobic exercise: (1) DNIC will be tested using a paradigm of two remote noxious stimuli with one, the 'conditioning stimulus' (immersing the hand in tub containing 8°c water), inhibiting the other, the 'test pain' (pressure pain threshold) in order to assess the endogenous analgesia (EA) efficiency (2) heat and pressure pain thresholds, and (3) temporal summation of painful heat and mechanical stimuli that reflect the neuroplasticity of the central nervous system following peripheral noxious stimulation. In addition, Anaerobic performance will be evaluated during Wingate test,and blood lactate will be measured. Gene related pain ill be tested using saliva samples .
Pantoea agglomerans is a Gram-negative bacterium commonly isolated from environmental sources such as plants and soil. Infections in humans are usually reported following penetrating wounds or in hospital settings due to contaminated medical equipment. Neonatal sepsis caused by this organism is rare. Late onset sepsis in neonatal intensive care units due to contaminated parenteral nutrition solutions has been reported. This case report describes early onset sepsis due to P agglomerans in an extremely preterm neonate, with no known maternal risk factors. The patient had a fulminant clinical course, multiorgan involvement and multiple serous cavity effusions. Timely antibiotics, supportive treatment and the use of neonatologist-performed bedside point-of-care ultrasound played an important role in management of complications and survival.
Interstitial cystitis (IC) is a chronic bladder disease for which the exact etiology is unknown and for which there is no reliably effective treatment. However, it is known that the bladder epithelium is often abnormal in IC. We discovered that human bladder epithelial cells from both normal controls and IC patients are inhibited from proliferating by an anti-proliferative factor (APF) present in IC urine specimens. Inhibited proliferation may cause eptithelium abnormalities characteristic of IC such as ulcerations and multiple tears in the bladder epithelium. We further discovered that 1) levels of heparin binding - epidermal growth factor-like growth factor (HB-EGF), a factor known to be important for epithelial cell proliferation and wound healing in other tissues, are abnormally low in the urine of patients suffering from IC as compared to asymptomatic controls or patients with acute bacterial cystitis; 2) the APF found in IC urine specimens inhibits HB-EGF production by bladder epithelial cells; and 3) that the administration of rHB-EGF blocks the effects of APF on bladder epithelial cells from either IC patients or controls. The invention herein is directed to the administration of HB-EGF, or a functional derivative or agonist thereof, to bladder epithelial cells to inhibit the effects of APF on bladder cell proliferation, thereby reducing or eliminating the chronic damage to the bladder epithelium. HB-EGF or a functional derivative may be used as a therapy for patients suffering from IC or other diseases characterized by inhibited epithelial cell proliferation.
The present invention provides a substantially purified polypeptide portion of a melanoma associated antigen, MG50 (SEQ ID NO: 2) and substantially purified T cell epitopes of MG50. For example, the invention provides a cytotoxic T cell epitope having the amino acid sequence RPRPEQUEPLP (SEQ ID NO: 4) and a helper T cell epitope having the amino acid sequence CSEQPFPEHTASVQHAD (SEQ. ID NO: 3). The invention also provides antibodies that specifically bind to MG50 or an MG50 T cell epitope and provides antigen binding fragments of such antibodies. Also provided are a substantially purified nucleic acid molecule (SEQ ID NO: 1), which encodes a portion of a melanoma associated antigen, MG50, and nucleic acid molecules encoding MG50 T cell epitopes. Vectors containing such nucleic acid molecules and cells containing such vectors also are provided. For example, antigen presenting cells containing a nucleic acid molecule of the invention are provided. The invention also provides methods of identifying an MG50 melanoma associated antigen in an individual and methods of identifying an immune response against an MG50 melanoma associated antigen in an individual. In addition, the invention provides methods of stimulating T lymphocytes that are reactive against cancer cells expressing an MG50 melanoma associated antigen and provides methods of treating an individual having cancer cells that express an MG50 melanoma associated antigen.
538,548. Calcium gluconate and glucoheptonate. ORGANON LABORATORIES, Ltd. June 12, 1940, No. 10248. Convention date, June 13, 1939. [Class 2 (ii)] [Also in Group VI]  A double salt' of calcium gluconate and calcium glucoheptonate is prepared in a solution containing at least 10 per cent. of calcium gluconate by dissolving the solid salts or by neutralizing the two acids with calcium carbonate or hydroxide. The salts usually require heating to dissolve them but the combined solution does not crystallize on cooling. By evaporating the solution or precipitating for instance with alcohol, the solid double salt is obtained. The solution is preferably sterilized by adding a preservative. In an example equimolecular proportions of the two salts are dissolved with heating, the solution being filtered and evaporated in vacuo. For injection the double salt is dissolved in water and sterilized by a little p-oxy-benzoic acid methyl ester, and after filling into flasks or ampoules re-sterilized by heating to 115‹ C. in an autoclave.
The aryl hydrocarbon receptor (AHR) is a receptor/transcription factor widely expressed in the lung. The physiological roles of AHR expressed in the alveolar epithelium remain unclear. In this study, we tested the hypothesis that alveolar epithelial AHR activity plays an important role in modulating inflammatory responses and maintaining alveolar integrity during lung injury and repair. AHR is expressed in alveolar epithelial cells (AECs) and is active. AHR activation with the endogenous AHR ligand, FICZ (5,11-dihydroindolo[3,2-b] carbazole-6-carboxaldehyde), significantly suppressed inflammatory cytokine expression in response to inflammatory stimuli in primary murine AECs and in the MLE-15 epithelial cell line. In an LPS model of acute lung injury in mice, coadministration of FICZ with LPS suppressed protein leak, reduced neutrophil accumulation in BAL fluid, and suppressed inflammatory cytokine expression in lung tissue and BAL fluid. Relevant to healing following inflammatory injury, AHR activation suppressed TGF-β-induced expression of genes associated with epithelial-mesenchymal transition. Knockdown of AHR in primary AECs with shRNA or in CRISPR-Cas-9-induced MLE-15 cells resulted in upregulation of α-smooth muscle actin (αSma), Col1a1, and Fn1 and reduced expression of epithelial genes Col4a1 and Sdc1. MLE-15 clones lacking AHR demonstrated accelerated wound closure in a scratch model. AHR activation with FICZ enhanced barrier function (transepithelial electrical resistance) in primary murine AECs and limited decline of transepithelial electrical resistance following inflammatory injury. AHR activation in AECs preserves alveolar integrity by modulating inflammatory cytokine expression while enhancing barrier function and limiting stress-induced expression of mesenchymal genes.
Synthetic drug development is slow and costly, often running into the billions of dollars. While the benefits of various abundant and inexpensive natural products, including natural oils and extracts, have been postulated and speculated upon for centuries, there has been very little success in achieving national approval (e.g. FDA approval) of natural compounds so that they can be used to benefit animals and patients. As many natural products are often complex and heterogenous, appropriate technologies for rapidly and efficiently predicting efficacy and toxicity of such natural compounds has been sorely lacking. Thus, there has been a long held and still unmet need to determine and teach appropriate health, veterinary, and medical uses for an orange, frankincense and cannabis products in a costeffective and efficient manner. Accordingly, the present invention teaches compositions, manufacture, products, and methods of use, prevention and treatment using at least one extract selected from the group comprising orange, frankincense, cannabis or other natural oil or extract or at least one substance or compound isolated from said at least one oil or extract (e.g. a cannabinoid, sesquiterpene, monoterpene, an ester, ether, aldehyde, phenylpropene, alcohol, ketone, phenol, etc.), so as to benefit medicine, human health and veterinary care. For example, the present invention teaches, the use of at least one extract selected from the group comprising orange, frankincense, cannabis or other natural oil or extract or at least one substance or compound isolated from said at least one oil or extract to reduce miR21 expression and thus treat/prevent cancer and psoriasis.
"Intra Operative Monitoring" (IOM) is a standard and routine medical practice for patients having MVD surgery. IOM is done to make sure that the hearing and face nerves are not accidentally bumped or damaged during surgery. After anesthetic induction, the neurophysiologist places electrodes for the nerves, on the scalp and muscles. Stimulation and monitoring of muscle twitches are all common, safe and painless medical procedures.

In this study, the investigators would like to measure the nerve and muscle function on the normal side and compare it to nerve and muscle function on the abnormal side during different levels of the anesthetic desflurane. In order to monitor the normal side of the face one additional set of electrodes will be placed in the facial muscles. The investigators will compare responses to three different levels of anesthetic. The technique used will be motor evoked potentials. The effect of the anesthesia on the lateral spread response will also be examined. This response is evident only on the symptomatic side. These observations will take approximately 10 to 15 minutes and will not delay or lengthen the surgery.
PURPOSE: An improved intestinal function, prevention of constipation, and treatment composite are provided by comprising proper mixture forming rate of herb medicine extract with active intestinal function. CONSTITUTION: A constipation therapeutic composite comprises at least one of selected group of lettuce, castor bean leaves, perilla seeds, and seaweed stream as the active ingredients. The extract is comprised as the 0.01-80 weight% of the total weight of the composite. According to the dried weight of the composite of extract, 20-15 weight% of lettuce, 20-50 weight% of castor bean leaves, 20-50 weight% of perilla seeds, and 20-50 weight% of seaweed streams are used. The extract is extracted as water, organic solvent, or mixture of those. The constipation therapeutic composite may be epigram type containing consperge, granule, decoct, capsule, suspension, emulsion, syrup, or aerosol type. The constipation therapeutic composite may be in a form of external preparation, suppository, and sterilization injection solution form.
Disclosed is a composition and method for a therapeutic treatment that is able to combat triple negative breast cancers (TNBCs). The class of urea compounds acts by blocking at inhibiting the mTOR signaling pathway, which, as a central regulator of mammalian metabolism and physiology that when inhibited leads to the induction of autophagocytosis. The disclosed compounds are further capable of reinitiating the p53 cycle as well as inhibition of the BNIP3/BNIP3L pathway. The disclosed compounds also shows the ability to cross the blood-brain-barrier where metastases can form. This new drug has the potential to be a powerful new treatment to combat invasive TNBCs. Formula (I).
In this trial, men with intermediate risk prostate cancer will be randomized to a shorter course of radiotherapy (6000cGy in 20 fractions over 4 weeks-hypofractionated) or treatment with a conventional fractionation course (7800cGy in 39 fractions over 8 weeks-standard). Three-dimensional conformal radiation treatment techniques, including intensity modulated radiotherapy will be used for both hypofractionated and standard treatments to avoid normal tissue exposure to radiation and minimize the risk of acute and late treatment related toxicity. The primary outcome measure is biochemical (PSA) failure defined by the ASTRO consensus criteria. Secondary outcomes include biochemical-clinical failure (BCF), mortality from cancer, toxicity and health-related quality of life. It is planned to recruit 1204 patients to the study. If the safety and efficacy of the shorter course are demonstrated, then its adoption would reduce the social, emotional and economic burden of treatment for patients and their families.
Patients in this group will receive Noninvasive brain stimulation: tDCS, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase.
Prescription drug abuse is the intentional non-therapeutic use of a drug, even once, for its rewarding psychological or physiological effects. Drug addiction, which develops after repeated drug abuse, is characterized by a strong desire to take a drug despite harmful consequences, difficulty in controlling its use, giving a higher priority to drug use than to obligations, increased tolerance, and sometimes physical withdrawal. Drug abuse and drug addiction are separate and distinct from physical dependence (for example, abuse may not be accompanied by physical dependence) [see Drug Abuse and Dependence (9.3)].

Studies of human abuse potential were performed to evaluate the abuse potential of FYCOMPA (8 mg, 24 mg, and 36 mg) as compared to alprazolam C-IV (1.5 mg and 3 mg), and oral ketamine C-III (100 mg) in recreational polydrug users. Supra-therapeutic doses of FYCOMPA 24 and 36 mg produced responses for “Euphoria” that were similar to ketamine 100 mg and alprazolam 3 mg. For “High,” FYCOMPA 24 mg and 36 mg produced responses comparable to ketamine 100 mg and significantly higher than both doses of alprazolam on a visual analog scale (VAS). “Drug Liking,” “Overall Drug Liking,” and “Take Drug Again” for FYCOMPA were each statistically lower than ketamine 100 mg. In addition, for “Bad Drug Effects,” FYCOMPA 24 mg and 36 mg produced responses significantly higher than ketamine 100 mg. For “Sedation,” FYCOMPA 24 and 36 mg produced responses similar to alprazolam 3 mg and higher than ketamine 100 mg. 

Additionally, on VAS measures related to dissociative phenomena such as “Floating,” “Spaced Out,” and “Detached,” FYCOMPA at supratherapeutic doses produced responses similar to ketamine 100 mg and greater than both doses of alprazolam tested. Of note, due to somnolence a number of subjects had missing data around Tmax of FYCOMPA. The above described data might represent an underestimate of FYCOMPA’s effects. The duration of effects of higher doses of FYCOMPA on the majority of measures was much greater than alprazolam 3 mg and ketamine 100 mg.

In this study, the incidence of euphoria following FYCOMPA administration 8 mg, 24 mg, and 36 mg was 37%, 46%, 46%, respectively, which was higher than alprazolam 3 mg (13%) but lower than ketamine 100 mg (89%).
A cell culture from sheep toetal kidney is inoculated with a measles virus stock which are allowed to grow in a culture medium, and then in a medium which nearly allows cellular degeneration. The viral prods. are then collected and the process repeated pref. 30-50 times until a product having at least 105 IDCT 50/ml titre and a haemoglutination power for monkey red blood cells, is formed. Pref. the stock used is Enders var. Edmonston and the incubation is at pref. 31-35 degrees C. Used in measles vaccines, or as antigens for its detection and antibody doses.
Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred in patients treated with 5-HT1 agonists, and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the 5-HT1 agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine, when they were not. Also, patients with migraine may be at increased risk of certain cerebrovascular events (e.g., stroke, hemorrhage, transient ischemic attack). Discontinue RizaFilm if a cerebrovascular event occurs.

Before treating headaches in patients not previously diagnosed with migraine or in patients who present with atypical symptoms, exclude other potentially serious neurological conditions. RizaFilm is contraindicated in patients with a history of stroke or transient ischemic attack.
The patients who have these moderate symptoms are fever of about 38,5-39 degrees celsius, chills, deep cough, fatigue and body aches, muscle pain, the general feeling of being unwell. Patients with bilateral diffuse pneumonia findings of radiological imaging or blood lymphocyte count \<800 / µl or serum CRP\> 40 mg / l or ferritin\> 500ng / ml or D-Dimer\> 1000 ng / ml will be included in group II.
OBJECTIVE: Sex-specific differences in the epidemiology of chronic kidney disease, such as higher prevalence of women on pre-dialysis and men on chronic dialysis treatment, have been reported worldwide. In this regard, data from non-high-income countries are scarce. We aimed to compare the demographic, clinical, and dialysis characteristics of incident dialysis patients, both men and women, in a large cohort of Brazilian patients over a 12-year period.
METHODS: This was a multicentric retrospective cohort study coordinated by the Brazilian Society of Nephrology. The study included all adult incident dialysis patients in the Brazilian Dialysis Registry from January 2011 to December 2022. The variables studied encompassed age, skin color, education, CKD etiology, predialysis nephrologist care, dialysis characteristics, and geographic region. Additionally, the sample was analyzed for each of the three 4-year periods over the 12 years of data collection.
RESULTS: A total of 24,632 incident dialysis patients were included. Men were 59.1% of the dialysis population, remaining stable over the three 4-year periods. Besides other differences, women started dialysis younger (58.5 ± 16.2 years vs 59.5 ± 14.4 years; p < 0.001), had a lower educational level (less than 8 years at school: 54% vs 44%; p < 0.001), received more predialysis nephrologist care (46.2% vs 44.2%; p = 0.04), and had a higher prevalence of peritoneal dialysis (4.4% vs 3.5%; p = 0.03).
CONCLUSION: We consistently observed a higher prevalence of men on dialysis and differences in demographic, clinical, and dialysis characteristics. The underlying reasons for these sex differences still necessitate further clarification.
Brothers as Allies is a strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years by addressing rigid beliefs and norms about masculinity that are harmful to the health, safety, relationships and opportunities of boys and young men. Groups of six to ten boys of similar age and development meet weekly with one or two facilitators for 1.5 to 2 hours for ten or more weeks. Meetings include warm up activities, an opportunity for check-in, experiential activities that address gender relevant topics (e.g., group challenges, games, skits, role plays), and a reflection and group dialogue component.
BACKGROUND: Rapid-eye movement (REM) sleep deprivation (SD) can induce manic-like behaviors in rodents. On the other hand, lithium, as one of the oldest drugs used in neuropsychiatric disorders, is still one of the best drugs for the treatment and control of bipolar disorder. In this study, we aimed to investigate the role of chronic short-term REM SD in the induction of manic-like behaviors in female rats.
METHODS: The rats were exposed to REM SD for 14 days (6 hours/day). Lithium was intraperitoneally injected at the doses of 10, 50, and 100 mg/kg.
RESULTS: REM SD induced hyperactivity and OCD-like behavior, and decreased anxiety, depressive-like behavior, and pain subthreshold. REM SD also impaired passive avoidance memory and decreased hippocampal brain-derived neurotrophic factor (BDNF) expression level. Lithium at the doses of 50 and 100 mg/kg partly and completely abolished these effects, respectively. However, lithium (100 mg/kg) increased BDNF expression level in control and sham REM SD rats with no significant changes in behavior.
CONCLUSIONS: Chronic short-term REM SD may induce a mania-like model and lead to OCD-like behavior and irritability. In the present study, we demonstrated a putative rodent model of mania induced by chronic REM SD in female rats. We suggest that future studies should examine behavioral and mood changes following chronic REM SD in both sexes. Furthermore, the relationship between manic-like behaviors and chronic REM SD should be investigated.